Ga 68 PSMA-11
- Generic Name
- Ga 68 PSMA-11
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C44H59GaN6O17
- CAS Number
- 1906894-20-9
- Unique Ingredient Identifier
- ZJ0EKR6M10
- Background
Gallium (Ga) 68 prostate-specific membrane antigen (PSMA)-11, or Ga-68 gozetotide, is a radiopharmaceutical agent used to identify and assess prostate-specific membrane antigen (PSMA)-positive lesions in adult men with prostate cancer during positron emission tomography (PET). Prostate cancer is one of the most commonly diagnosed cancers among men in Western...
- Indication
Gallium Ga-68 gozetotide, or Gallium Ga-68 PSMA-11, is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer metastasis with:
- Associated Conditions
- Prostate-specific Membrane Antigen Positive Tumors
- Associated Therapies
- -
Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- University of Iowa
- Target Recruit Count
- 30
- Registration Number
- NCT02952469
- Locations
- 🇺🇸
Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- Andrei Iagaru
- Target Recruit Count
- 74
- Registration Number
- NCT02678351
- Locations
- 🇺🇸
Stanford University, School of Medicine, Palo Alto, California, United States
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
- First Posted Date
- 2016-02-03
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- Andrei Iagaru
- Target Recruit Count
- 61
- Registration Number
- NCT02673151
- Locations
- 🇺🇸
Stanford University, School of Medicine, Palo Alto, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.